Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide inhalation - Aerami Therapeutics

Next Previous
Drug Profile

Exenatide inhalation - Aerami Therapeutics

Alternative Names: AER-601; AER-601 - Soft-mist Inhaled Exenatide; Dance-601; GLP-1 analogue - Aerami Therapeutics

Latest Information Update: 20 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dance Biopharm
  • Developer Aerami Therapeutics
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 20 Sep 2023 Preclinical development in Type-2-diabetes-mellitus is still ongoing in USA (Inhalation, Liquid) (Aerami Therapeutics pipeline, September 2023)
  • 28 May 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (Inhalation, Liquid)
  • 22 Mar 2023 Aerami Therapeutics plans a phase I/IIa for Type 2 diabetes mellitus (Inhalation) (Aerami Therapeutics pipeline, March 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top